This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Tyrosinemia / Hereditary Tyrosinemia Type I·II·III / FAH deficiency타이로신혈증 (타이로신대사장애 / 타이로신증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E70.2 (tyrosinemia; same code as alkaptonuria but a separate disease) | OMIM: 276700 (HT1/FAH), 276600 (HT2/TAT), 276710 (HT3/HPD) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsTyrosinemia, tyrosine metabolism disorder, tyrosinosis, hereditary tyrosinemia type I (HT1/FAH deficiency), hereditary tyrosinemia type II (HT2/tyrosine aminotransferase deficiency/Richner-Hanhart syndrome), hereditary tyrosinemia type III (HT3/HPD deficiency)
C. Adult onsetLikelihood of first onset in adulthood low (HT1·HT2) / rare (HT3) — HT1 mostly presents a few months after birth in the acute form and in childhood in the chronic form; in HT2, keratopathy and skin lesions may first appear up to adolescence or early adulthood; in untreated HT1, hepatocellular carcinoma (HCC) may occur in adulthood.
1. History1956 Baber first described HT1 → 1970s FAH gene identified → 1992 Lindstedt et al. first reported the clinical effect of NTBC (nitisinone) → 1992 molecular cause of Richner-Hanhart syndrome (HT2) identified → 2002 U.S. FDA approved nitisinone.
2. CausesHT1: FAH gene (15q25.1) variant → fumarylacetoacetate hydrolase deficiency → accumulation of the toxic metabolite succinylacetone. HT2: TAT gene (16q22.1) variant → tyrosine aminotransferase deficiency. HT3: HPD gene (12q24.31) variant → 4-hydroxyphenylpyruvate dioxygenase deficiency.
3. GeneticsAll three types are autosomal recessive. HT1: FAH (15q25.1), c.1062+5G>A (IVS12+5G>A) is the Quebec, Canada founder variant; various variants reported in Korea. HT2: TAT (16q22.1). HT3: HPD (12q24.31). OMIM 276700/276600/276710.
4. General epidemiologyWorldwide incidence of HT1 about 1:100,000–1:120,000. High incidence of 1:1,846 in parts of Quebec, Canada. HT1 is rarely reported in Korea. HT2: about 150 cases worldwide. HT3: on the order of several dozen cases. Equal incidence in males and females.
5. PathophysiologyHT1: FAH deficiency → accumulation of fumarylacetoacetate (FAA)/maleylacetoacetate (MAA) → formation of succinylacetone → DNA damage in liver and kidney cells, inhibition of porphobilinogen synthase (ALAD) (neuropathic crises), development of HCC. HT2/III: elevated blood tyrosine → crystal deposition in cornea and skin.
6. SymptomsHT1 (acute): infantile liver failure (coagulopathy, jaundice, ascites), renal tubular dysfunction (Fanconi syndrome). HT1 (chronic): cirrhosis, hepatocellular carcinoma, decreased renal function, porphyria-like neurological crises (abdominal pain, flaccid paralysis). HT2: corneal lesions, palmoplantar hyperkeratosis, intellectual disability (some). HT3: mild neurological symptoms, ataxia, mental retardation.
7. SignsHT1: hepatomegaly, markedly elevated serum AFP (marker of hepatocellular injury/HCC), prolonged PT, elevated blood tyrosine and methionine, positive urine/serum succinylacetone, Fanconi syndrome (hypophosphatemia, aminoaciduria). HT2: conjunctival and corneal lesions (slit lamp), palmoplantar hyperkeratosis. HT3: mild tyrosinemia.
8. ScreeningNewborn screening (MS/MS): measurement of blood tyrosine (low sensitivity) vs. measurement of urine/serum succinylacetone (specific for HT1, excellent sensitivity and specificity). Some countries use DBS succinylacetone as the first-line screening biomarker for HT1. Tyrosine is included in expanded newborn screening in Korea.
9. DiagnosisPlasma amino acids (elevated tyrosine, methionine). Urine/serum succinylacetone (specific for HT1). Urine organic acid analysis. Serum AFP. Liver function tests, coagulation tests. FAH/TAT/HPD gene NGS panel. Liver tissue FAH enzyme activity (if needed). Abdominal ultrasound and MRI (to differentiate liver nodules).
10. TreatmentHT1: nitisinone (NTBC/Orfadin®) — blocks toxic metabolites by inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPD), plus a low-tyrosine diet. With early treatment, liver function recovers and HCC risk decreases. Liver transplantation (if NTBC-refractory or with HCC). HT2/III: low-tyrosine, low-phenylalanine diet therapy.
11. PrognosisHT1 (early NTBC): markedly improved survival, greatly reduced HCC incidence (5–10%). Before the introduction of nitisinone, survival was often <5 years, but long-term survival is now possible. Blood AFP is an indicator of treatment response and HCC surveillance. HT2: corneal and skin symptoms improve with diet therapy. HT3: prognosis relatively good.
12. PreventionPrimary: genetic counseling, carrier and prenatal genetic testing. Secondary: newborn DBS succinylacetone measurement (early detection of HT1), start NTBC immediately. Tertiary: regular AFP and abdominal ultrasound (HCC surveillance, at 6-month intervals), liver and renal function monitoring, dietary tyrosine control, genetic counseling and family support.
13. ReferencesLindstedt S et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992. and 9 other papers

1. History

The history of tyrosinemia begins with Baber's first report in 1956 of an infant case with liver failure and markedly elevated blood tyrosine. After this early report, through the 1960s–70s, the clinical picture of what came to be called "hepatorenal tyrosinemia" accumulated through numerous cases. In particular, an abnormally high incidence was observed in the Charlevoix-Saguenay-Lac-Saint-Jean region of Quebec, Canada, confirming a clustering of the genetic disease owing to the founder effect, and the incidence in this region was reported to reach 1:1,846.

In the 1970s, deficiency of fumarylacetoacetate hydrolase (FAH), the last enzyme in the tyrosine degradation pathway, was identified as the cause of hereditary tyrosinemia type 1 (HT1). Subsequently, the pathogenesis was elucidated: succinylacetone, a toxic intermediate metabolite that cannot be broken down because of FAH deficiency, causes severe damage to liver and kidney cells and inhibits porphobilinogen synthase (ALAD), causing porphyria-like neurological crises.

The most important turning point in HT1 treatment was the study published in Lancet in 1992 by Lindstedt et al. in Sweden. They demonstrated clinically for the first time that nitisinone (NTBC: 2-[2-nitro-4-trifluoromethylbenzoyl]-1,3-cyclohexanedione) blocks the formation of FAA and succinylacetone by competitively inhibiting HPD. This discovery provided a groundbreaking non-surgical treatment option for HT1 patients, for whom liver transplantation had previously been the only treatment (PMID: 1353658). After large-scale clinical trials, nitisinone was approved by the U.S. FDA in 2002 and the European EMA in 2005.

HT2 (Richner-Hanhart syndrome) became known when Richner in 1938 and Hanhart in 1947 independently described patients with corneal abnormalities and skin lesions. In 1992 the tyrosine aminotransferase (TAT) gene was identified as the cause of HT2. HT3 was found in 2002 to result from HPD gene deficiency and is a very rare disease.

HT1 patients have been rarely reported in Korea, and molecular genetic analysis of the FAH gene has identified various pathogenic variants. In Korea, nitisinone is currently covered by insurance as a rare disease treatment and is managed under the Special Copayment Reduction code V117. Introduction of serum succinylacetone measurement for early detection of HT1 in newborn screening is being discussed.


2. Causes

Tyrosinemia results from deficiency of enzymes at different steps of the tyrosine catabolic pathway, and is classified into three main subtypes according to the causative enzyme and clinical picture.

Hereditary tyrosinemia type 1 (HT1, OMIM #276700): It results from deficiency of fumarylacetoacetate hydrolase (FAH), located at the last step of the tyrosine degradation pathway. The FAH gene is located on the long arm of chromosome 15 (15q25.1). In FAH deficiency, fumarylacetoacetate (FAA) and maleylacetoacetate (MAA) accumulate in the liver and kidney and are converted to succinylacetone (SA). SA is a potent cytotoxin that causes double-strand breaks in hepatocyte DNA, inhibits alpha-ketoglutarate dehydrogenase, and inhibits ALAD, causing porphyria-like neuropathic crises. In addition, chronic hepatocellular injury markedly increases the risk of cirrhosis and hepatocellular carcinoma (HCC). HT1 is the most severe of the three subtypes and is clinically the most important.

Hereditary tyrosinemia type 2 (HT2, Richner-Hanhart syndrome, OMIM #276600): It results from deficiency of tyrosine aminotransferase (TAT), which catalyzes the first step of tyrosine degradation in the liver. The TAT gene is located on the long arm of chromosome 16 (16q22.1). Blood tyrosine is markedly elevated, and tyrosine crystals are deposited in the cornea and the skin of the palms and soles. Liver and kidney function are unaffected or only mildly affected.

Hereditary tyrosinemia type 3 (HT3, OMIM #276710): It results from deficiency of 4-hydroxyphenylpyruvate dioxygenase (HPD). The HPD gene is located on the long arm of chromosome 12 (12q24.31). It is characterized by moderate elevation of blood tyrosine and mild neurological symptoms, and is the rarest of the three subtypes. Importantly, HPD is also the enzyme inhibited by nitisinone (NTBC), so HT3 is biochemically similar to the state of secondary HPD inhibition caused by NTBC.

All three subtypes follow autosomal recessive inheritance, so there is a 25% recurrence risk for a child between carrier parents. In HT1, FAH gene variants are diverse, and the Quebec, Canada founder variant IVS12+5G>A (c.1062+5G>A) is representative.


3. Genetics

All three subtypes of tyrosinemia follow autosomal recessive inheritance. The causative gene and genetic features of each subtype are as follows.

FAH gene (HT1): Located on the long arm of chromosome 15 at q25.1, 14 exons, OMIM *613871. More than 100 pathogenic variants have been reported worldwide. The Quebec, Canada founder variant IVS12+5G>A (splicing variant) accounts for about 90% of the allele frequency in this population. The Norwegian founder variant p.Pro261Leu is also known. In reports of Korean HT1 patients, various missense and splicing variants have been identified. Genotype-phenotype correlation of FAH gene variants has been shown for some variants such as IVS12+5G>A, but overall it is difficult to predict the clinical course from the variant type alone. Interestingly, small cell populations in which normal FAH function has been restored (revertant mosaic) are sometimes observed in the hepatocytes of HT1 patients; these arise from somatic reversion owing to a selective growth advantage and are known to play a role in alleviating clinical symptoms in some patients.

TAT gene (HT2): Long arm of chromosome 16 at q22.1, OMIM *613018. Only about 150 cases have been reported worldwide. More cases are reported relatively frequently in the Mediterranean region and the Middle East. Variants are diverse, including missense, nonsense, and splicing variants.

HPD gene (HT3): Long arm of chromosome 12 at q24.31, OMIM *609695. A very rare subtype, on the order of several dozen cases. Some patients previously classified as having moderate tyrosinemia were confirmed to have HPD deficiency.

In terms of genetic counseling, all three subtypes carry a 25% risk of affected children from carrier parents. In confirmed patients, targeted variant analysis of siblings and prevention in subsequent pregnancies through prenatal diagnosis or PGT-M are possible. In patients with FAH gene variants in Korea, targeted testing based on a list of specific variants frequently identified domestically may be useful.


4. General epidemiology

The three subtypes of tyrosinemia each have different epidemiological characteristics. Hereditary tyrosinemia type 1 (HT1) is the most common of the three subtypes, with a worldwide incidence reported at about 1:100,000–1:120,000. However, in the Charlevoix-Saguenay-Lac-Saint-Jean region of Quebec, Canada, an abnormally high incidence of 1:1,846 has been reported owing to the founder effect, making this region the center of HT1 research. Relatively high frequencies have also been identified in parts of Scandinavia, the Middle East, Turkey, and India.

HT1 is reported very rarely in Korea, remaining at the level of case reports from large domestic medical institutions, and accurate incidence data are lacking. Tyrosine is included in expanded newborn screening, but in the early stage of HT1 blood tyrosine may be normal or only mildly elevated, so there are limits to early detection unless succinylacetone is used as the first-line biomarker.

HT2 is an extremely rare disease, with only about 150 cases reported worldwide. It is reported relatively more often in people from the Mediterranean region (Italy, Spain), the Middle East, and North Africa. Reports of HT2 in Korea are extremely rare. HT3 is even rarer, on the order of several dozen cases worldwide. Sex distribution is equal in all three subtypes.

Worldwide, with the expansion of newborn screening and the introduction of succinylacetone measurement, early detection of HT1 is increasing, and the proportion of patients who start nitisinone treatment in the asymptomatic period before clinical manifestation is rising. This trend is contributing greatly to improving the prognosis of HT1 patients.


5. Pathophysiology

The pathophysiology of each subtype of tyrosinemia is determined by the location of the relevant enzyme and the toxicity of the metabolites that accumulate owing to the defect.

Pathophysiology of HT1: The tyrosine degradation pathway proceeds from tyrosine → 4-hydroxyphenylpyruvate (4-HPP, catalyzed by HPD) → homogentisic acid (HGA, catalyzed by HGD) → maleylacetoacetate (MAA) → fumarylacetoacetate (FAA, broken down by FAH into fumaric acid + acetoacetic acid). In FAH deficiency, FAA and MAA accumulate and act as highly reactive electrophiles. They deplete intracellular glutathione (GSH) and cause DNA double-strand breaks and mitochondrial dysfunction, leading to necrosis and death of hepatocytes and proximal tubular cells. FAA also reacts with homogentisic acid to produce succinylacetone. SA is a potent inhibitor of porphobilinogen synthase (ALAD), causing impaired heme synthesis, accumulation of delta-aminolevulinic acid (δ-ALA), and porphyria-like neuropathic crises (severe abdominal pain, flaccid paralysis, respiratory failure). Chronic DNA damage and abnormal hepatocyte proliferation increase the risk of cirrhosis and hepatocellular carcinoma (HCC).

Pathophysiology of HT2: TAT deficiency blocks tyrosine transamination in the liver, so blood tyrosine is markedly elevated (500–3,500 μmol/L). Supersaturated tyrosine crystallizes around the abundant nerve endings of the cornea and the palms and soles, causing inflammatory reactions (keratitis, skin hyperkeratosis). The toxic metabolites FA and MAA are not produced, so there is no liver or kidney damage.

Pathophysiology of HT3: HPD deficiency blocks the conversion of 4-HPP to HGA, so 4-HPP, 4-hydroxyphenyllactic acid (4-HPLA), and 4-hydroxyphenylacetic acid (4-HPA) accumulate and blood tyrosine is moderately elevated. The mechanism of neurotoxicity is not fully elucidated, but accumulation of downstream metabolites in the brain is presumed to cause the mild neurological symptoms.


6. Symptoms

The clinical picture of tyrosinemia differs greatly by subtype.

HT1 — acute form: The most severe phenotype, presenting within several weeks to 6 months after birth. It is characterized by acute liver failure (jaundice, ascites, abdominal distension, hypoglycemia) and severe coagulation factor deficiency (markedly prolonged PT/aPTT). Without treatment, death from liver failure may occur within weeks to months. Renal tubular dysfunction (Fanconi syndrome: glycosuria, phosphaturia, aminoaciduria, hypercalciuria) accompanies, with growth retardation and a rickets-like picture.

HT1 — chronic form: It presents after 6 months of age, with progressive hepatomegaly, cirrhosis, and renal tubular dysfunction. Hepatocellular carcinoma (HCC) can occur even in childhood if early treatment is not received, and long-term HCC surveillance is needed even with nitisinone treatment. Porphyria-like neuropathic crises are a distinctive clinical feature of HT1, with sudden severe abdominal pain, flaccid peripheral paralysis, autonomic abnormalities (hypertension, tachycardia), and respiratory failure due to respiratory muscle paralysis. Triggers include fever, infection, and fasting.

HT2 (Richner-Hanhart): The main symptoms are bilateral corneal lesions (dendritic corneal ulcers, photophobia, epiphora, decreased vision) and painful hyperkeratotic lesions of the palms and soles. Mild to moderate intellectual disability accompanies in some patients. There are no liver or kidney symptoms.

HT3: The main symptoms are mild neurological symptoms (ataxia, seizures, delayed mental development). Corneal and skin lesions are absent or mild. Because the clinical symptoms are mild, diagnosis may be delayed.


7. Signs

The main clinical signs of tyrosinemia are as follows.

HT1-specific signs: Marked elevation of serum alpha-fetoprotein (AFP) is the most important indicator of hepatocellular injury and hepatocellular carcinoma. In HT1 neonates, AFP remains at a much higher level than in normal neonates and decreases after nitisinone treatment. Positive succinylacetone in urine and serum is the pathological marker specific to HT1. Hepatomegaly, splenomegaly, and ascites may be found on physical examination. Findings related to Fanconi syndrome: decreased blood phosphate, increased urinary glucose, phosphate, and amino acids, and increased blood alkaline phosphatase (ALP). Abnormal coagulation tests (prolonged PT/aPTT, decreased fibrinogen).

HT2-specific signs: On slit-lamp examination, corneal pseudodendritic lesions (pseudodendritic keratitis) and opacity. Painful hyperkeratotic plaques of the palms and soles. Plasma tyrosine markedly elevated at 500–3,500 μmol/L.

HT3 signs: Moderately elevated plasma tyrosine (200–600 μmol/L). Increased urinary 4-HPP, 4-HPLA, and 4-HPA. Neurological abnormalities (cerebellar atrophy on MRI, etc.).

In all tyrosinemias, elevated tyrosine (and methionine in HT1) is commonly found on plasma amino acid analysis. In HT1, elevated AST, ALT, and total bilirubin are observed on liver function tests.


8. Screening

Newborn screening for tyrosinemia uses two approaches: measurement of blood tyrosine (MS/MS) and measurement of succinylacetone.

Blood tyrosine measurement (MS/MS): Most national newborn screening programs measure blood tyrosine as part of expanded screening. However, in the early stage of HT1 blood tyrosine may be normal or only mildly elevated, so measuring tyrosine alone has low sensitivity for HT1. In addition, false positives are frequent in transient neonatal tyrosinemia (premature infants, vitamin C deficiency, etc.). In contrast, in HT2 blood tyrosine is markedly elevated and is detected sensitively.

Succinylacetone (SA) measurement: SA is a biomarker specific to HT1, and when measured by MS/MS on dried blood spots (DBS) it shows high sensitivity and specificity for HT1. In the United States, Canada, Germany, Japan, and elsewhere, SA is included as a first-line biomarker in newborn screening, with reports of a better early detection rate of HT1 than tyrosine-only screening. Introduction of SA measurement makes it possible to detect HT1 in the asymptomatic neonatal period and start nitisinone treatment before liver damage occurs. In Korea as well, discussion is under way on introducing SA into the expanded newborn screening program.

Family screening and follow-up testing: After confirmation of HT1, screening of siblings and genetic testing of carrier parents are recommended. In subsequent pregnancies, prenatal diagnosis (FAH gene testing via chorionic villus sampling or amniocentesis, or urine SA measurement) is possible.


9. Diagnosis

Confirmation of tyrosinemia is made through biochemical testing and molecular genetic testing.

Quantitative plasma amino acid analysis: Elevated tyrosine and methionine are characteristic in HT1. In HT2, tyrosine is markedly elevated (500 μmol/L or more). In HT3, tyrosine is moderately elevated.

Urine/serum succinylacetone (SA) measurement: A specific indicator that is key to confirming HT1. Measured by gas chromatography-mass spectrometry (GC-MS) or tandem mass spectrometry. A positive SA strongly suggests HT1.

Urine organic acid analysis: Increase in 4-hydroxyphenyl organic acids (4-HPP, 4-HPLA, 4-HPA) (all three subtypes). SA, succinylacetylacetone, etc. (HT1-specific).

Liver function and coagulation tests: AST, ALT, total bilirubin, PT/aPTT, and fibrinogen in HT1.

Serum AFP: Markedly elevated in HT1. Used for monitoring treatment response and HCC surveillance.

FAH/TAT/HPD gene NGS panel testing: Confirmation and subtype determination by identifying pathogenic variants. When the causative gene is unclear, a broad panel including tyrosine metabolism genes or whole exome sequencing (WES) is used.

Liver tissue FAH enzyme activity measurement: Used adjunctively when molecular testing is uncertain. Liver biopsy is performed taking into account the risk in HT1, in which coagulopathy is already present.

Abdominal ultrasound and MRI/CT: Evaluation of liver size, degree of cirrhosis, and liver nodules (to differentiate HCC). In HT1 patients, abdominal ultrasound at 6-month intervals is the standard for HCC surveillance.


10. Treatment

Treatment of tyrosinemia takes a different approach for each subtype.

HT1 — nitisinone (Orfadin®) treatment: It competitively inhibits 4-hydroxyphenylpyruvate dioxygenase (HPD), blocking the tyrosine degradation pathway at a step before the formation of the toxic intermediate metabolites of HT1 (FAA, MAA). As a result, urine and serum succinylacetone disappear rapidly and liver function improves markedly. The dose is 0.5–2 mg/kg/day orally according to body weight, and the goal is complete suppression of blood succinylacetone. Because blood tyrosine rises further owing to HPD inhibition when nitisinone is given, a low-tyrosine, low-phenylalanine diet must be combined. The target blood tyrosine is kept below 700 μmol/L. The earlier treatment is started (neonatal period), the more markedly the risk of HCC decreases.

Liver transplantation: Liver transplantation is indicated in HT1 that does not respond to nitisinone, acute liver failure, and established HCC. After liver transplantation, FAH enzyme activity is restored, and nitisinone and dietary restriction become unnecessary. However, FAH deficiency persists in extrahepatic tissues (kidney, brain), so neuropathic crises may rarely occur even after transplantation in some patients.

HT2 and HT3 — low-tyrosine, low-phenylalanine diet therapy: Because phenylalanine is converted to tyrosine in the body, a special diet that restricts both amino acids is the core of treatment. Along with supplementation with a tyrosine-free amino acid formula, the blood tyrosine target level (400–600 μmol/L or below) is maintained. With diet therapy, corneal and skin lesions improve markedly.

Management of acute porphyria crises (HT1): High-dose glucose infusion and use of safe analgesics. Intravenous haem arginate is used in some cases. Avoid crisis triggers (infection, fasting).


11. Prognosis

The prognosis of tyrosinemia is determined by the subtype and the timing of treatment initiation.

HT1 — before the introduction of nitisinone: The acute form often led to death from liver failure within several months after birth, and even in the chronic form the mean age of survival was under 12 years. At the time when liver transplantation was the only treatment, survival improved greatly, but transplantation itself carried risks.

HT1 — after the introduction of nitisinone: The long-term survival of HT1 patients treated with nitisinone plus a low-tyrosine diet has improved markedly. In cohorts diagnosed in the neonatal period and treated early, asymptomatic survival and normal growth and development are reported. However, the risk of HCC does not disappear completely even with long-term nitisinone treatment, so regular AFP and abdominal imaging surveillance are needed for life. The incidence of HCC during nitisinone treatment is estimated to have decreased from 50–80% in the past to about 5–10%. Neuropathic crises (porphyria-like) are well controlled with nitisinone.

HT2: Corneal and skin lesions improve markedly within a few months after dietary therapy is started. When intellectual disability is present, full recovery of cognitive function is uncertain. Prognosis is good with early treatment.

HT3: Has the best prognosis among the subtypes; daily functioning can be maintained with dietary therapy and symptom management. However, the number of cases is extremely small, so long-term prognosis data are insufficient.


12. Prevention

Prevention of tyrosinemia aims at early detection, early initiation of treatment, and prevention of long-term complications (including HCC).

Primary prevention: Genetic counseling and carrier testing for families with a confirmed diagnosis. Thereafter, early detection of affected fetuses in pregnancy by prenatal genetic diagnosis (FAH/TAT/HPD gene testing via chorionic villus sampling or amniocentesis) or PGT-M. In regions with a high incidence of HT1 (Quebec, Scandinavia) in particular, population genetic counseling is actively carried out.

Secondary prevention (newborn screening): Including succinylacetone (SA) measurement in the first-tier screening on newborn DBS markedly improves the early detection rate of HT1. If the screen is positive, confirmatory tests (plasma amino acids, urine organic acids, AFP) are performed immediately and nitisinone treatment is started promptly. The earlier treatment is started, the more intervention is possible before liver damage occurs.

Tertiary prevention (management of long-term complications): In HT1 patients, a surveillance program of regular AFP measurement and abdominal ultrasound (every 6 months) and liver MRI (when needed) for early detection of hepatocellular carcinoma is essential. Blood SA, tyrosine, and AFP are monitored regularly to optimize the nitisinone dose. This includes management of dietary adherence, follow-up of renal function and bone density, and avoidance of triggers of neuropathic crises (early treatment of fever, minimizing fasting).


13. References

  1. Lindstedt S, Holme E, Lock EA, et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992;340(8823):813-817. DOI: 10.1016/0140-6736(92)92685-9
  2. Grompe M. The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin Liver Dis. 2001;21(4):563-571. DOI: 10.1055/s-2001-19034
  3. de Laet C, Dionisi-Vici C, Leonard JV, et al. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis. 2013;8:8. DOI: 10.1186/1750-1172-8-8
  4. van Ginkel WG, Jahja R, Huijbregts SCJ, et al. Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls. Orphanet J Rare Dis. 2016;11(1):87. DOI: 10.1186/s13023-016-0472-5
  5. Chinsky JM, Singh R, Ficicioglu C, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017;19(12):1380. DOI: 10.1038/gim.2017.101
  6. Bijarnia-Mahay S, Bhatia S, Bhatt T, et al. Hereditary tyrosinemia type 1: clinical, biochemical, and molecular characterization. J Pediatr Genet. 2019;8(2):73-82. DOI: 10.1055/s-0038-1676628
  7. Arranz JA, Riudor E. Significance of succinylacetone testing in the diagnosis of type I hereditary tyrosinaemia. Acta Paediatr. 2005;94(12):1822-1823. DOI: 10.1111/j.1651-2227.2005.tb01858.x
  8. Hühn R, Stoermer H, Klingele B, et al. Novel and recurrent tyrosine aminotransferase gene mutations in tyrosinemia type II. Hum Genet. 1998;102(3):305-313. DOI: 10.1007/s004390050696
  9. Ellaway CJ, Holme E, Standing S, et al. Outcome of tyrosinaemia type III. J Inherit Metab Dis. 2001;24(8):824-832. DOI: 10.1023/a:1013924210249
  10. Mayorandan S, Meyer U, Gokcay G, et al. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. Orphanet J Rare Dis. 2014;9:107. DOI: 10.1186/s13023-014-0107-7